Acetylcarnitine could influence the cholinergic system as a cholinergic receptor agonist, promoting synthesis and release of acetylcholine [42], and it has been reported that Acetylcarnitine dysregulation usually occurs in neurological disorders [43–45], Zhao et al. have demonstrated that low Acetylcholinesterase expression was discovered in hepatocellular carcinoma tissue and had significantly associated with high risk of cancer recurrence and poor survival [46]. This evidence concerns the gene ACHE and hepatocellular carcinoma.